Overview
The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.
Description
Recombinant tissue plasminogen activator (alteplase) is currently the recommended treatment of AIS in patients within 0 to 4.5 hours from symptom onset. The cost of a single treatment with this drug is around 5000 RMB (about 700 USD). In contrast, the cost of a single dose of urokinase is around 300 RMB (about 40 USD), making it much more affordable. Currently, existing evidence regarding the effectiveness and safety of urokinase is mixed. Some studies propose that urokinase thrombolysis, compared with alteplase thrombolysis, improves perfusion without increasing the incidence of adverse reactions and mortality. In some cases, using urokinase for thrombolysis even lowers the risk of systemic bleeding, comparing to alteplase. Other studies suggest that the effectiveness and safety of urokinase intreating AIS patients is infeiror comparing to alteplase . In this study, we plan to conduct a nationwide multicenter real-world study on urokinase intravenous thrombolysis with alteplase as an active control. We will observe and analyze AIS patients treated with urokinase and alteplase and compare the effectiveness, safety and economic effects. We will explore different urokinase dosage efficacy indicators and analyze relevant risk factors. This will provide data for future systematic evaluations of the clinical effects of urokinase thrombolysis which may help lower the medical costs in treating AIS while ensuring the effectiveness.
Eligibility
Inclusion Criteria:Age: ≥18 years. Clinical diagnosis of acute ischemic stroke, defined as
an event characterized by the sudden onset of an acute focal neurologic deficit, unilateral
motor dysfunction or impairment of language presumed to be due to cerebral ischemia after,
with imaging evidence of a causative lesion or symptoms/signs persisting for over 24 hours.
CT scan should exclude hemorrhage and non-vascular etiology.
First-time occurrence or a history of stroke without significant neurological deficits
(baseline mRS score ≤ 1).
Eligible for treatment with intravenous administration of urokinase or alteplase as
assessed by the investigators.
Patient is willing to participate voluntarily and to sign a written patient informed
consent. Informed consent will be obtained from each patient or the subject's legally
authorized representative or relatives, or deferred where applicable.
-
Exclusion Criteria:Contraindications for thrombolysis (refer to the 2018 Chinese Guidelines
for the Diagnosis and Treatment of Acute Ischemic Stroke, intravenous thrombolysis
contraindications).
Female of childbearing potential who is known to be pregnant and/or lactating or who has a
positive pregnancy test on admission.
Known history of drug (narcotics, controlled substances) abuse or addiction in the past
year.
Has an expected survival of less than 90 days due to concurrent malignant tumors or severe
systemic diseases Incapable to comply with the protocol due to mental illness or cognitive
disorder.
Paticipants of any interventional drug or device clinical trials within 3 months prior to
screening.
Unsuitable for this study in the opinion of the investigators.
-